{"pub": "yahoo", "url": "https://finance.yahoo.com/news/alexion-acquire-achillion-pharma-930m-112506573.html", "downloaded_at": "2019-10-17 06:01:16.688408+00:00", "title": "Alexion To Acquire Achillion Pharma For $930M", "language": "en", "text": "Alexion Pharma (NASDAQ: ALXN) will buy Achillion Pharma (NASDAQ: ACHN) for the initial value of $930 million, or $6.30 per share in cash plus added contingent considerations for total potential value of $8.30 per share.\n\nAlexion will also be acquiring the cash currently on Achillion's balance sheet and as of Sept. 30, this was approximately $230 million.\n\nThe Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch\n\n\"Alexion has demonstrated the transformative impact that inhibiting C5 can have on multiple rare and devastating diseases. However, we believe this is just the beginning of what's possible with complement inhibition,\" said Ludwig Hantson, CEO of Alexion.\n\nAchillion Pharma shares were trading higher by 85% at $6.75 in Wednesday\u2019s pre-market session.\n\nSee more from Benzinga\n\n\u00a9 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.", "description": "Alexion Pharma (NASDAQ: ALXN ) will buy Achillion Pharma (NASDAQ: ACHN ) for the initial value of $930 million, or $6.30 per share in cash plus added contingent considerations for total potential value ...", "authors": ["Tanzeel Akhtar"], "top_image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo.png", "published_at": "2019-10-16"}